Upcoming Events

November 1-2, 2013

Conference: Blinding Science 

Hosted by the Edmond J. Safra Center for Ethics at Harvard University.
Co-sponsored by the Petrie-Flom Center.

November 6, 2013

PRIM&R Annual Conference: Harvard Reception

Hynes Convention Center, Boston

Cosponsored by the Petrie-Flom Center and the Division of Medical Ethics at Harvard Medical School.

November 7, 2013, 12:00pm

Reproductive Rights around the Globe: A Panel Discussion

Cosponsored by the Petrie-Flom Center and the Human Rights Program at Harvard Law School. 

November 8, 2013, 12:00pm

Ethics and Animals: Where Are We Now?

A lecture by Peter Singer, Ira W. DeCamp Professor of Bioethics, University Center for Human Values, Princeton University

Co-sponsored by the Petrie-Flom Center and Harvard High-Impact Philanthropy.

Past Events (2012-2013)

September 19, 2012

What Money Can't Buy: The Moral Limits of Markets

The Center co-sponsored an event where Professor Michael Sandel gave a lecture introducing his new book What Money Can’t Buy: The Moral Limits of Markets. His talk focused on two main arguments: There should be certain norms that govern our relationship with certain goods; and markets corrupt these norms.

September 25, 2012

Health Care Reform: A View from Both Sides

The Center hosted a special off-the-record debate on American health care reform, moderated by the Petrie-Flom Center’s Founding Faculty Director,  Einer Elhauge.  John McDonough, official surrogate of the Obama campaign and director of the Center for Public Health Leadership at the Harvard School of Public Health, and Oren Cass, domestic policy director for the Romney campaign, discussed what each candidate would mean for the future of US health policy.

Wednesday, October 10, 2012

Patients with Passports: Medical Tourism, Law and Ethics

Wednesday, October 24, 2012

Open Access to Health Research: Future Directions for the NIH Public Access Policy

 In 2008, the NIH Public Access Policy became a statutory mandate, requiring  "that all investigators funded by the NIH submit or have submitted for them to the National Library of Medicine's PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication." As a way to stimulate progress in health research and clinical practice, as well as relieve a financial burden on a public who must otherwise rely exclusively on highly expensive journal subscriptions to access tax-funded research, the NIH Policy has already been deemed a success.  In the past 4 years, the mandatory NIH Public Access Policy has brought compliance rates up from 4% to roughly 75%, however, there is still work to be done. What are the strategies that institutions and researches should be considering to address that remaining 25% "non-compliance" with the NIH Public Access Policy? How can we further expand public access to tax-funded research articles, and support our faculty and students in this endeavor? 

Institutional Open Access resolutions such as Harvard’s Open Access Policy have helped accommodate the NIH Public Access Policy requirements, but as yet, medical schools have been slow to adopt institutional level open access policies, including Harvard Medical School and Harvard School of Public Health  - What have been the challenges? Furthermore, in May, the Harvard Library Faculty Advisory Council issued a public letter calling on faculty to promote open access scholarly publishing, noting "Many large journal publishers have made the scholarly communication environment fiscally unsustainable and academically restrictive".  Howcan we work together to help achieve each of these goals and expand Open Access to biomedical and health research?

In recognition of Open Access Week 2012, four distinguished panelists  explored the challenges and opportunities for increasing NIH Public Access Policy compliance and open access efforts at Harvard:

• Peter Suber,
  Director of the Harvard Open Access Project, Berkman Center Fellow, author of Open Access
  
  
• Amy Brand, 
  Assistant Provost for Faculty Appointments and Information
  
  
• Winston Hide, 
  HSPH Professor of Bioinformatics and Computational Biology
  
  

• Patrick Taylor, 
  Assistant Clinical Professor of Pediatrics, Harvard Medical School;  Director of Ethics Analysis and Applications in the Informatics Program and Staff Scientist, Children's Hospital Boston, (Formerly Chief Counsel for Research Affairs at Children's Hospital and Former Academic Fellow at the Petrie-Flom Center).
  

Moderators: 

• Scott Lapinski,
   HMS Digital Resources and Services Librarian and Open Access Liaison,
  
  
• June Casey, HLS Librarian for Open Access and Scholarly Communication

The panel was followed by two brief "101" sessions on individual-level implementation of both the NIH's Public Access and Harvard's Open Access mandates.

Co-sponsored by the Office of Scholarly Communications, the Right to Research Coalition & Universities Allied for Essential Medicines & HLS Advocates for Human Rights

Thursday, November 1, 2012

Book Talk and Panel Discussion Obamacare on Trial

• I. Glenn Cohen, Faculty co-Director, Petrie-Flom Center, Harvard Law School
  
  
• Abigail Moncreiff, Boston University School of Law
  
  
• Sanford Levinson, University of Texas Austin Law School
  
  
• John McDonough, Harvard School of Public Health

Friday, November 2, 2012

8:30am-6:30pm
Reception 6:30-8:00pm

Insitutional Financial Conflicts of Interest in Research Universities

Monday, November 5, 2012

Advances in HIV Prevention: Legal, Clinical, and Public Health Issues

On July 3, 2012, FDA approved OraQuick, the first at-home HIV test available for sale directly to consumers, allowing individuals to self-test and receive confidential results in about 20 minutes. Then on July 16, FDA approved once-daily Truvada, an already-approved HIV therapy, as the first agent approved for pre-exposure prophylaxis in uninfected, at-risk adults. These developments represent dramatic changes in the fight against HIV, and raise a host of legal, clinical, and public health issues. The Petrie Flom Center hosted a panel discussion of these issues with some of the preeminent leaders in the field, which was moderated by Robert Greenwald, Director of the Center for Health Law and Policy Innovation:

• Douglas A. Michels, President and CEO, OraSure Technologies, Inc.



• David Piontkowsky, Senior Director for Medical Affairs, HIV and HIV Global Medical Director, Gilead Sciences, Inc.
  
  
• Kenneth H. Mayer, Medical Research Director, Co-Chair of The Fenway Institute
  
  
• Kevin Cranston, Director, Bureau of Infectious Disease, Massachusetts Department of Public Health
  
  
• Mark Barnes, Partner, Ropes Gray, Lecturer in Law, Harvard Law School
  Co-sponsored by the Petrie-Flom Center, the Center for Health Law and Policy Innovation, and the Fenway Institute.  

Tuesday, November 13, 2012

The Guatemala STD Inoculation Studies: What Should We Do Now?

In the late 1940s, US and Guatemalan researchers conducted a host of experiments on vulnerable Guatemalan subjects, purposefully exposing them to and infecting them with a number of STDs without their consent.  The experiments were kept hidden for more than half a century, until they were discovered and exposed only recently by historian Susan Reverby.  The US government has since apologized for what happened, but a class action suit brought on behalf of the Guatemalan subjects was dismissed in June and efforts to directly compensate the victims have not been forthcoming.   In conjunction with Harvard Law School's Human Rights Program the Center hosted a panel discussion of the study and possible legal and political responses that may be available now, both domestically and from an international human rights perspective.  Panelists included:

• Susan Reverby, Marion Butler McLean Professor in the History of Ideas, Professor of Women's and Gender Studies, Wellesley College
  
  
• I. Glenn Cohen, Assistant Professor of Law, Faculty Co-Director, Petrie-Flom Center, Harvard Law School
  
  
• Holly Fernandez Lynch, Executive Director, Petrie-Flom Center, Lecturer on Law, Harvard Law School
  
  
• Wendy Parmet,  George J. and Kathleen Waters Matthews Distinguished University Professor of Law, Northeastern University School of Law
  
  
• Fernando Ribeiro Delgado, Clinical Instructor and Lecturer on Law, Human Rights Program, Harvard Law School

Tuesday, November 13th, 2012

Massachusetts: A Community Approach to Quality, Affordable Health Care

Andrew Dreyfus, President and CEO of Blue Cross Blue Shield Massachusetts

Six years after passing the groundbreaking health care access law that became the model for national reform, Massachusetts has once again led the nation through legislation setting a limit on the growth of health care cost.  What progress has the state’s health care community made on cost so far, and what will it take to improve quality and meet the new cost growth standards?  Come hear the perspective of Andrew Dreyfus, President and CEO of Blue Cross Blue Shield Massachusetts and leader of the company’s efforts to create one of the largest commercial payment reform initiatives in the nation. 

Wednesday, November 28, 2012

Stem Cell Therapy and Medical Tourism: Of Promise and Peril?

Experimental breakthroughs within the field of regenerative medicine are reported in the media on a daily basis worldwide.  Despite this progress, the overwhelming majority of clinical problems for which stem cell-based intervention offers hope remain therapeutically unproven, and a major gap exists between current public understanding and the availability of innovative therapies. 

This event featured a distinguished panel of speakers addressing various aspects of medical tourism for stem cell therapy.  Presentations covered the state of stem cell science, historical context and comparisons related to earlier instances of medical utopianism, empirical data on the nature of stem cell tourism, how to address patient hopes in the realm of unproven therapies, and special issues related to stem cell tourism by parents for their children.

The event was moderated by M. William Lensch, Harvard Stem Cell Institute.  Speakers and topics included:

• Brock Reeve, Harvard Stem Cell Institute
  Welcome and Introductions
  
  
• George Q. Daley, Harvard Stem Cell Institute
  Stem Cells: The Gap Between Current Science and Clinical Implementation
  
  
• Jill Lepore, Harvard University
  Resurrection, Past and Present
  
  
• Tim Caulfield, University of Alberta -
  Stem Cell Tourism: Is the Problem Getting Worse?
  
  
• Insoo Hyun, Case Western Reserve University School of Medicine
  Therapeutic Hope and Its Challenges for Rational Ethical Discourse
  
  
• I. Glenn Cohen, Petrie-Flom Center, Harvard Law School -
  Stem Cell Tourism, Children, Abuse, and Reporting

 Co-sponsored by the Harvard Stem Cell Institute and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

Thursday, November 29, 2012

Nourishing a Legal Career in the Life Sciences

Please join us for a career discussion with Amy Schulman, Lecturer on Law at HLS, Executive Vice President and General Counsel at Pfizer, Inc., President and General Manager of Pfizer Nutrition, and Mark Nance, Senior Vice President and General Counsel at Mylan, Inc. The discussion will be moderated by Professor David Wilkins.

Co-sponsored by the Program on the Legal Profession, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, and the HLS Office of Career Services. 

Thursday, January 17, 2013

Food & Drug Law: Past, Present & Future
Celebrating Peter Barton Hutt’s 20 Years (thus far) at HLS

Peter Barton Hutt has worked at the Washington, DC law firm of Covington & Burling, specializing in Food and Drug Law, for more than five decades. He has represented clients in administrative, legislative, executive, and judicial settings. He began his law practice with the firm in 1960 and is now Senior Counsel; between 1971 to 1975, he was Chief Counsel for the Food and Drug Administration. The Best Lawyers in America selected Mr. Hutt as the 2013 FDA Lawyer of the Year for Washington, DC. Since 1994, Mr. Hutt has taught Food and Drug Law during Winter Term at Harvard Law School, covering all aspects of government regulation of food and drugs from ancient times to present.

Introductions and Welcome
Martha Minow, HLS Dean

Tributes to Professor Hutt

• I. Glenn Cohen, Assistant Professor, Harvard Law School; Faculty Co-Director, Petrie-Flom Center
• Theodore Ruger, Professor of Law, Penn Law School
• Lewis Grossman, Professor of Law, American University Washington College of Law

Reflections
Peter Barton Hutt

Questions and Discussion
Dean Minow and Audience
Co-sponsored by the Petrie-Flom Center and the HLS Dean's Office

Friday, February 1, 2013

Health Law Year in P/Review

1:00-5:00pm (reception to follow)
Wasserstein Hall 2036, Milstein East C
Harvard Law School

Please join us for the first annual Health Law Year in P/Review event, bringing together leading experts to review some of the most important changes in the health law landscape over the past year, their implications for the future, and a preview of what is to come.  

Our inaugural session will feature the following topics and presenters:

The ACA and Health Care Reform

•  Einer Elhauge
• Jonathan Gruber

Personhood Amendments and Contraceptives Coverage

• I. Glenn Cohen
• Holly Fernandez Lynch 

Immigrants' Access to Health Care

•  Wendy Parmet  

Affirmative Action and Medical School Admissions

• Renee Landers

Gene Patenting

• Aaron Kesselheim

Tobacco and Obesity Policy and the First Amendment

•  Kevin Outterson

Summary and Wrap Up

•  Kristin Madison

Remarks from Dean Martha Minow at 3:15

A wine and cheese reception will follow at 5:00pm.

For questions, please contact petrie-flom@law.harvard.edu, 617-496-4662.  
Co-sponsored by the Petrie-Flom Center at Harvard Law School and the New England Journal of Medicine.

Monday, February 18, 2013

Compliance with and Enforcement of US Healthcare Laws: Evolution of Modern Life Sciences Compliance Programs

There have been a number of recent prosecutions of life sciences companies under the Food, Drug, and Cosmetic Act and the qui tam whistleblower provisions of the False Claims Act.  Allegations include things like unlawful promotion, failure to report safety data, and false price reporting practices, resulting in massive settlements, some in the billion dollar range.

Understandably, compliance has become a top priority for life sciences companies, which typically have dedicated compliance programs in place with ever more sophisticated internal programs for educating employees, preventing wrongful conduct, detecting and deterring violations, and ensuring prompt remedial action.  

Please join us for a panel discussion of how life science compliance efforts have evolved in recent years to face a variety of challenges.  We'll hear from some of the leading experts from the government, life sciences industry, private bar, and academia:   

1. Mary Riordan, Senior Counsel, Department of Health and Human Services, Office of the Inspector General (OIG)
2. James Sheehan, Chief Integrity Officer, NYC Human Resources Administration; Former Medicaid Inspector General for New York State  
3. Paul Kalb, Partner, Healthcare Practice head, Life Sciences Practice global coordinator, Sidley Austin   
4. Kathleen Boozang, Professor of Law, Seton Hall 
5. Moderator: Kris Curry, Vice President, Health Care Compliance, Pharmaceuticals Group, Johnson & Johnson

Lunch will be served.  Open to the public.
Contact petrie-flom@law.harvard.edu with questions.

With support from the Oswald DeN. Cammann fund

Background Materials available for download here.

Friday, March 1, 2013

Charles Fried on Evidence as a Public Good

1:00-2:00pm
Vorenberg Classroom, Langdell 225, Harvard Law School

We hear a lot about the conflict between use of an individual's information for the public good and that individual's privacy concerns. In this talk organized by PFC Academic Fellow Michelle Meyer, Charles Fried, Beneficial Professor of Law at Harvard, will examine the deeper conflict that arises when an individual is used to generate information-public or private-in the first place. Professor Fried will thus revisit some of the foundational questions that animated his groundbreaking 1974 book, Medical Experimentation: Personal Integrity and Social Policy. 

With support from the Oswald DeN. Cammann fund 

Monday, March 4, 2013

Rethinking Personhood: Fetuses, Animals, and Robots

Are there entities that we do not (or would not) recognize as persons but should, or entities that we do (or would) recognize as persons but should not?  Should fetuses, animals, or artificial intelligences have rights? On what grounds should we recognize the moral and legal standing of others?   Please join us for a panel discussion on these and related questions with leading experts who will look to entities whose status is unclear or contested in order to rethink the nature of moral and legal personhood.

• I. Glenn Cohen, Harvard Law School
• Alice Crary, Philosophy, New School for Social Research
• Lawrence B. Solum, Georgetown Law
• Moderator: Jeffrey M. Skopek, Academic Fellow, Petrie-Flom Center

Lunch will be served.  Open to the public.
Contact petrie-flom@law.harvard.edu with questions.

Co-sponsored by the Harvard Law School Human Rights Program

Wednesday, March 6, 2013

Personalized Medicine Patenting

Pharmaceutical researchers pursue medical treatment and diagnostic methods to target diseases specific to certain demographic groups.  Such pursuit is often motivated by commercialization through patenting.  Are these research innovations a solution to orphan diseases?  Or do they foster a culture of niche, designer medicine? 

This lecture, based on the recently published book "Identity, Invention, and the Culture of Personalized Medicine Patenting" (Cambridge 2012), by Professor Shubha Ghosh of the University of Wisconsin Law School, examines these questions through discussion of BiDil, the first drug FDA approved specifically for the African-American population; Myriad's patented diagnostic method for identifying breast cancer in Ashkenazi Jewish women; Prometheus' patent for treating Crohn's Disease (invalidated by the Supreme Court in 2012 in an infringement suit by Prometheus against the Mayo Clinic); and other provocative examples at the intersection of patent and health law.

Professor Benjamin Roin, Heiken Assistant Professor in Patent Law at Harvard and Petrie-Flom Center Faculty co-Director, will serve as discussant.

Lunch will be served.  Open to the public.
Contact petrie-flom@law.harvard.edu with questions.

March 8-9, 2013

Forum on Food Labeling: Putting the Label on the Table

The Petrie-Flom Center is pleased to be co-sponsoring the Harvard Law School Food Law Society's second annual conference, Forum on Food Labeling: Putting the Label on the Table.  As a part of the Society's mission to foster dialogue and exchange knowledge of emerging issues in food policy and regulation, this conference will explore the legal and policy aspects of food labeling and its effects on consumer knowledge, choice, and behavior. The forum will bring together a host of authorities on food law and policy to raise discussion on a number of pressing questions, including: What should we know about what's in our food and how it is grown? What considerations should inform these decisions? Are food labels a meaningful tool to encourage better nutrition choices?
  
Register for the conference here.

Wednesday, April 3, 2013

Harvard Law School Program of Study: Law, Science, and Technology Student Advisory Lunch

Thursday, April 4, 2013

Revising the Requirement of Informed Consent in an Era of Privatization and Managed Care

Please join us for a discussion with Daniel Sperling, Petrie-Flom Center Short-Term Visiting Fellow and Senior Lecturer in Bioethics, Health Law, and Health Policy, The Federmann School of Public Policy & Government and Braun School of Public Health & Community Medicine, The Hebrew University of Jerusalem. Dr. Sperling will present his current research project, with a response from HLS Professor and Petrie-Flom Faculty Co-Director, I. Glenn Cohen

Abstract: With the increased realization that healthcare is delivered in a complex system changing over time and the prominence of managed care organizations in some places or the rise of private health systems in others, the legal discussion of informed consent has gradually changed. Surprisingly (or not), the bioethical literature has expressed little interest in such changes. Dr. Sperling will explore this recent phenomenon, provide an explanation for the lack of interest in the new revisions made to the principle of informed consent, and discuss the implications of these changes for bioethics more generally.  

Lunch will be served.  Open to the public. No registration required.

Contact petrie-flom@law.harvard.edu with questions.

Thursday, April 8, 2013

Film Screening: deepsouth

Cosponsored by the Center for Health Law and Policy Innovation

April 18-19, 2013

Universal Coverage in Developing Country Health Systems: Ethical Dilemmas

Friday and Saturday, May 3-4, 2013

Petrie-Flom Center Annual Conference:
The Food and Drug Administration in the 21st Century

Wasserstein Hall, Milstein East ABC, Harvard Law School

Attendance is free and open to the public.  Registration required; space is limited. Contact petrie-flom@law.harvard.edu with questions.

Conference Description

The Food and Drug Administration, the US government’s oldest comprehensive consumer protection agency, bears the monumental task of safeguarding the public health through regulation of food, drugs and biologics, devices, cosmetics, animal products, radiation-emitting products, and now, tobacco. The agency faces a number of perennial issues related to funding, relationships with industry, and striking the proper balance between consumer choice and consumer protection. It also faces several modern challenges related to globalization, novel technologies, newly added responsibilities, and changing threats to the public health.

How is the agency faring in the 21st century? What are the greatest challenges to the FDA’s success, and what does success look like? What lessons has it learned and how can it best meet the challenges of today? Should we keep the agency we have, pull it apart, or rebuild from scratch?   This conference will  gather leading experts from academia, government, and private industry to evaluate the FDA based on these and other questions, and to begin charting a course for the agency’s future.

Conference Sessions

* For the full conference agenda, including speakers, presentation titles, and specific times, please click here. *

DAY 1 – Friday, May 3, 2013, 9:00-5:00

• Welcome and Introduction
• PLENARY 1 - PETER BARTON HUTT (Covington & Burling)
• The FDA in a Changing World
• Preserving Public Trust and Demanding Accountability
• LUNCH AND KEYNOTE by DEBORAH AUTOR (Deputy Commissioner for Global Regulatory Operations and Policy, U.S. Food and Drug Administration), with an introduction by JEFFREY SENGER (Sidley Austin)
• Protecting the Public Within Constitutional Limits
• Timing Is Everything: Balancing Access and Uncertainty
• Major Issues in Drug Regulation

DAY 2 – Saturday, May 4, 2013, 9:00-4:00

• Welcome
• PLENARY 2 - ALTA CHARO (University of Wisconsin Law School)
• Regulatory Exclusivities and the Regulation of Generic Drugs and Biosimilars
• Major Issues in Device Regulation
• LUNCH AND PLENARY 3 - SUSAN WINCKLER (President and CEO, Food & Drug Law Institute)
• Major Issues in Food, Supplement, and Tobacco Regulation
• Addressing the Challenges of and Harnessing New Technologies
• Closing Remarks

Register Now!

Friday, May 17, 2013

Issues and Case Studies in Clinical Trial Data Sharing – What Have We Learned?

Co-sponsored by the Multi-Regional Clinical Trial Center at Harvard University, and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School

Objectives:

• To convene key global stakeholders on a neutral platform to review evidence from recent case studies in clinical trial data disclosure

• To discuss key areas of learning and potential solutions for clinical trial data sharing that may inform policy in this important area moving forward

• To discuss implications of data sharing initiatives for pharmaceutical regulation in the U.S. and other countries

Please see the conference page for registration information. A final agenda, featuring keynote speakers Dr. Jeff Drazen (NEJM) and Dr. Albert J. “AJ” Allen (Lilly) as well as regulators from US, EMA, Canada, Japan, Russia and other countries, may be viewed here. 

You may also view pre-conference video interviews, providing an introduction to some of the issues to be discussed, by clicking the following links:

• Dr. Steven Nissen (Cleveland Clinic)
• Dr. Deborah Zarin (NIH)
• Dr. Yaniv Erlich (Whitehead Institute) 

Contact mrct@harvard.edu with any questions.

Tuesday, September 17, 12:00pm

Patient Discrimination against Medical Personnel

Wasserstein Hall 3019, Harvard Law School, 1585 Massachusetts Ave.

We don't stand for doctors discriminating against patients on the basis of race, but what about when the tables are turned? At this event, Kimani Paul-Emile of Fordham Law School will lead a discussion of her new article in the UCLA Law Review, Patients' Racial Preferences and the Medical Culture of Accommodation.  Renee Landers of Suffolk Law School and Dr. Fidencio Saldana of Harvard Medical School and Brigham and Women's and Faulkner Hospitals will serve as discussants. 

Monday, September 23, 4:00pm

Gene Patenting, the Supreme Court's Myriad Decision, 
and the Future of Biotechnology: A Panel Discussion 

Austin 100, Harvard Law School, 1515 Massachusetts Ave.

Moderated by Dean Martha Minow of Harvard Law School, this event will focus on the impact of the Supreme Court's recent decision that naturally occurring DNA cannot be patented. Will this be a boon for patients and a burden for biotech companies?  Will sufficient incentive remain for innovation?  Will there be any practical change at all?  

Panelists will include Eric Lander, Director of the Broad Institute of MIT and Harvard, Professor of Biology at MIT, and Professor of Systems Biology at Harvard Medical School; Claire LaPorte, Partner, Foley Hoag LLP; and Tania Simoncelli, former Science Advisor to the ACLU. I. Glenn Cohen and Ben Roin, Faculty Co-Directors of the Petrie-Flom Center, will moderate. 

Co-sponsored by the Broad Institute of MIT and Harvard.

Monday, September 23, 6:00pm

Petrie-Flom Center Annual Open House

Austin West Rotunda

Come learn more about what the Petrie-Flom Center does and how you can get involved at this gathering for faculty, colleagues, and students with shared interests in health law policy, biotechnology, and bioethics.

Tuesday, September 24, 12pm

Book Launch: The Globalization of Health Care, edited by I. Glenn Cohen

Wasserstein Hall 3019, Harvard Law School, 1585 Massachusetts Ave.

I. Glenn Cohen, Faculty Co-Director of the Petrie-Flom Center and Professor at Harvard Law School, will discuss his new edited volume, recently out from Oxford University Press, The Globalization of Health Care: Legal and Ethical Issues.  The book ties together the manifestation of health care globalization in four related subject areas - medical tourism, medical migration (physician "brain drain"), telemedicine, and pharmaceutical research and development, and integrates them in a philosophical discussion of issues of justice and equity. 

The event will also feature a panel discussion with Dr. Sue Goldie, Faculty Director of the Harvard Global Health Institute and Director of the Center for Health Decision Science at the Harvard School of Public Health, and Dr. Neel T. Shah, Founder and Executive Director of Costs of Care and Assistant Professor at Harvard Medical School and Beth Israel Deaconess Medical Center. Einer Elhauge, Petrie Professor of Law at Harvard Law School and Founding Director of the Petrie-Flom Center, will moderate.